August 3, 2018
FDA issues warning on azithromycin
Editor's Note
The Food and Drug Administration (FDA) on August 3 issued a warning for azithromycin, saying the antibiotic should not be given long-term to prevent an inflammatory lung condition in patients with cancers of the blood or lymph nodes who undergo a donor stem cell transplant.
A clinical trial has found an increased rate of relapse in cancers, including death, in these patients. The FDA is reviewing additional data and will issue recommendations when the review is complete.
Free Daily News
- FDA: Surgical mesh mini-slings comparable to mid-urethral slings for stress urinary incontinence
- Federal guidelines require written consent for pelvic exams at hospitals, medical schools
- Survey: More than half of ED nurses experienced violence in past month
- Heart transplant research proves out 24-hour organ preservation method
- Healthcare safety report: Outcomes improving, but workplace violence persists
- Annual CMS rules support underserved, under-resourced communities, promote value-based care
- Data resource details causes, health implications of sleep deprivation
- Medical error initiative from Joint Commission affiliate NQF targets preventable harm, “never events”
- EPA rule to limit dangerous emissions from medical sterilization plants
- Newly FDA-approved microsurgical system holds promise for training, new treatments
© Access Intelligence, LLC. All rights reserved. | Privacy Policy | Diversity, Equity, Inclusion & Belonging